Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies

Clinical Cancer Research

Volumn 19, Issue 2, 2013, Pages 347-356

  Mao, Yicheng ^a,b   Triantafillou, Georgia ^a   Hertlein, Erin ^a   Towns, William ^a   Stefanovski, Matthew ^a   Mo, Xiaokui ^b   Jarjoura, David ^b   Phelps, Mitch ^b   Marcucci, Guido ^a   Lee, Ly James ^c   David M Goldenberg, ^d   Lee, Robert J ^b   Byrd, John C ^a,b,e   Muthusamy, Natarajan ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Ohio State University   (United States)

^d CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; DEXAMETHASONE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLIPOSOME; MILATUZUMAB; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CD74- B CELL; CD74- T CELL; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAJI CELL; SCID MOUSE; T LYMPHOCYTE; TARGET CELL DESTRUCTION; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL LINE, TUMOR; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKEMIA, B-CELL; LIPOSOMES; LYMPHOMA, B-CELL; MICE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872565342     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2046     Document Type: Article

References (50)

1. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Prog 2004;163-83.
2. Greenstein S, Ghias K, Krett NL, Rosen ST. Mechanisms of glucocorticoid- mediated apoptosis in hematological malignancies. Clin Cancer Res 2002;8: 1681-94.
3. Friedenberg WR, Tallman MS, Brodsky I, Paietta E, Rowe JM, Lee SJ, et al. Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group. Leuk Res 2004;28: 813-19.
4. Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16: 2092-95.
5. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid- induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004;11 Suppl 1:S45-55.
6. Iglesias-Serret D, de FriasM, Santidrián AF, Coll-Mulet L, Cosialls AM, Barragan M, et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2006;21: 281-87.
7. Almawi WY, Melemedjian OK, Jaoude MM. On the link between Bcl-2 family proteins and glucocorticoid-induced apoptosis. J Leukocyte Biol 2004;76: 7-14.
8. Gine E, Crespo M, Muntanola A, Calpe E, Baptista MJ, Villamor N, et al. Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. Haematologica 2008;93: 75-82.
9. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104: 1428-34.
10. Cooper MS. Sensitivity of bone to glucocorticoids. Clin Sci (Lond) 2004;107: 111-23.
11. Kronenberg H, Williams RH. Williams textbook of endocrinology (11th ed.). Philadelphia, PA: Saunders/Elsevier; 2008.
12. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004;8: 335-53.
13. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19: 1444-54.
14. Lowis S, Lewis I, Elsworth A, Weston C, Doz F, Vassal G, et al. A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. Br J Cancer 2006;95: 571-80.
15. Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res. 2002;8: 413-18.
16. Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, Boerman OC, Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003;48: 2059-66.
17. Rauchhaus U, Kinne RW, Pohlers D, Wiegand S, Wolfert A, Gajda M, et al. Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann Rheum Dis 2009;68: 1933-34.
18. Schiffelers RM, Metselaar JM, Fens MH, Janssen AP, Molema G, Storm G. Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 2005;7: 118-27.
19. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62: 7190-94.
20. Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2000;60: 6942-49.
21. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8: 1172-81.
22. Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of doxorubicin-Loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody. Drug Delivery 2007;14: 171-75.
23. Hegeman M, Cobelens P, Kamps J, Hennus MP, Jansen NJ, Schultz MJ, et al. Liposome-encapsulated dexamethasone attenuates ventilator- induced lung inflammation. Br J Pharmacol 2011;163: 1048-1058.
24. Asgeirsdottir SA, Zwiers PJ, Morselt HW, Moorlag HE, Bakker HI, Heeringa P, et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol 2008;294:F554-61.
25. Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, et al. Anti- CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005;11: 5257-64.
26. Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, et al. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003;9: 6567-71.
27. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, ChangCH, Burton J, et al. CD74: anew candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:5556s-63s.
28. Hertlein E, Triantafillou G, Sass EJ, Hessler JD, Zhang X, Jarjoura D, et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2010;116: 2554-58.
29. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87: 4990-97.
30. Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112: 5180-89.
31. Li N, Hill KS, Elferink LA. Analysis of receptor tyrosine kinase internalization using flow cytometry. Methods Mol Biol 2008;457: 305-317.
32. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000;95: 3929-38.
33. Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 2011;117: 4530-41.
34. Hansen HJ, Ong GL, Diril H, Valdez A, Roche PA, Griffiths GL, et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996;320: 293-300.
35. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004;10: 6606-11.
36. Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Release 2004;94: 155-61.
37. Avnir Y, Ulmansky R, Wasserman V, Even-Chen S, Broyer M, Barenholz Y, et al. Amphipathic weak acid glucocorticoid prodrugs remoteloaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheumatism 2008;58: 119-29.
38. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 2001;24: 903-20.
39. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden- Ledbetter MS, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007;110: 2569-77.
40. Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, et al. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res 2008;14: 569-78.
41. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96: 2655-63.
42. Christian B, Alinari L, Earl CT, Wilding CQ, Lustberg M, Benson DM, et al. A Phase I study of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 2010;116 Abstract nr 2788.
43. Kaufman J, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, et al. Dose-escalation trial of milatuzumab (humanized anti- CD74 monoclonal antibody) in multiple myeloma. J Clin Oncol 27:15s, 2009 (suppl; abstr 8593).
44. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 1988;85: 6949-53.
45. Anderson R, Franch A, Castell M, Perez-Cano FJ, Brauer R, Pohlers D, et al. Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res Ther 2010;12:R147.
46. Smith LK, Cidlowski JA. Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes. Prog Brain Res 2010;182: 1-30.
47. Planey SL, Litwack G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 2000;279: 307-12.
48. Tuckermann JP, Kleiman A, McPherson KG, Reichardt HM. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci 2005;42: 71-104.
49. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5: 505-15.
50. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51: 691-743.